The global antispasmodic and anticholinergic H2 blocking agents market is expected to grow at a CAGR of 4.5% during the forecast period, to reach USD 3.6 billion by 2030. The growth of this market is driven by the increasing prevalence of gastrointestinal disorders such as irritable bowel syndrome (IBS) and chronic constipation, which are major indications for these drugs.
The oral segment accounted for the largest share in 2017 due to its wide range of applications such as intestinal and renal colic cramps, diarrhoea, spastic constipation, gastritis, dysmenorrhea among others. The parenteral segment is expected to grow at a CAGR of 5% during the forecast period owing to its high efficacy in treating acute conditions such as asthma attacks or allergic reactions that require immediate treatment with these drugs.
-The global Antispasmodic and Anticholinergic H2 Blocking Agents market is expected to grow at a CAGR of 3.5% during the forecast period.
-The global Antispasmodic and Anticholinergic H2 Blocking Agents market is expected to reach USD 1,890 million by 2023 from USD 1,600 million in 2017.
-Increasing prevalence of gastrointestinal disorders such as irritable bowel syndrome (IBS) and ulcerative colitis are driving the growth of the global Antispasmodic and Anticholinergic H2 Blocking Agents market.
Industry Growth Insights published a new data on “Antispasmodic and Anticholinergic H2 Blocking Agents Market”. The research report is titled “Antispasmodic and Anticholinergic H2 Blocking Agents Market research by Types (Oral, Parenteral, Topical, Others), By Applications (Intestinal and Renal Colic Cramps, Diarrhoea, Spastic Constipation, Gastritis, Dysmenorrhea, Others), By Players/Companies Demeton, Alaven Pharmaceutical, lriSys, Meda Pharmaceuticals, Fougera Pharmaceuticals, Valeant Pharmaceuticals International, LUITPOLD PHARMS, FOREST LABS INC, MylanPharmaceuticals, Pioneer Pharmaceuticals, Watson Laboratories, Lannett”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Antispasmodic and Anticholinergic H2 Blocking Agents Market Research Report
By Type
Oral, Parenteral, Topical, Others
By Application
Intestinal and Renal Colic Cramps, Diarrhoea, Spastic Constipation, Gastritis, Dysmenorrhea, Others
By Companies
Demeton, Alaven Pharmaceutical, lriSys, Meda Pharmaceuticals, Fougera Pharmaceuticals, Valeant Pharmaceuticals International, LUITPOLD PHARMS, FOREST LABS INC, MylanPharmaceuticals, Pioneer Pharmaceuticals, Watson Laboratories, Lannett
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
233
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Antispasmodic and Anticholinergic H2 Blocking Agents Market Report Segments:
The global Antispasmodic and Anticholinergic H2 Blocking Agents market is segmented on the basis of:
Types
Oral, Parenteral, Topical, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Intestinal and Renal Colic Cramps, Diarrhoea, Spastic Constipation, Gastritis, Dysmenorrhea, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Demeton
- Alaven Pharmaceutical
- lriSys
- Meda Pharmaceuticals
- Fougera Pharmaceuticals
- Valeant Pharmaceuticals International
- LUITPOLD PHARMS
- FOREST LABS INC
- MylanPharmaceuticals
- Pioneer Pharmaceuticals
- Watson Laboratories
- Lannett
Highlights of The Antispasmodic and Anticholinergic H2 Blocking Agents Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Parenteral
- Topical
- Others
- By Application:
- Intestinal and Renal Colic Cramps
- Diarrhoea
- Spastic Constipation
- Gastritis
- Dysmenorrhea
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Antispasmodic and Anticholinergic H2 Blocking Agents Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Antispasmodic and anticholinergic agents are medications that block the action of nerve impulses. This can relieve symptoms of spasm, such as pain, cramps, and tightness.
Some of the major players in the antispasmodic and anticholinergic h2 blocking agents market are Demeton, Alaven Pharmaceutical, lriSys, Meda Pharmaceuticals, Fougera Pharmaceuticals, Valeant Pharmaceuticals International, LUITPOLD PHARMS, FOREST LABS INC, MylanPharmaceuticals, Pioneer Pharmaceuticals, Watson Laboratories, Lannett.
The antispasmodic and anticholinergic h2 blocking agents market is expected to grow at a compound annual growth rate of 4.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Antispasmodic and Anticholinergic H2 Blocking Agents Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Antispasmodic and Anticholinergic H2 Blocking Agents Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Antispasmodic and Anticholinergic H2 Blocking Agents Market - Supply Chain
4.5. Global Antispasmodic and Anticholinergic H2 Blocking Agents Market Forecast
4.5.1. Antispasmodic and Anticholinergic H2 Blocking Agents Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Antispasmodic and Anticholinergic H2 Blocking Agents Market Size (000 Units) and Y-o-Y Growth
4.5.3. Antispasmodic and Anticholinergic H2 Blocking Agents Market Absolute $ Opportunity
5. Global Antispasmodic and Anticholinergic H2 Blocking Agents Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Antispasmodic and Anticholinergic H2 Blocking Agents Market Size and Volume Forecast by Type
5.3.1. Oral
5.3.2. Parenteral
5.3.3. Topical
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Antispasmodic and Anticholinergic H2 Blocking Agents Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Antispasmodic and Anticholinergic H2 Blocking Agents Market Size and Volume Forecast by Application
6.3.1. Intestinal and Renal Colic Cramps
6.3.2. Diarrhoea
6.3.3. Spastic Constipation
6.3.4. Gastritis
6.3.5. Dysmenorrhea
6.3.6. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Antispasmodic and Anticholinergic H2 Blocking Agents Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Antispasmodic and Anticholinergic H2 Blocking Agents Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Antispasmodic and Anticholinergic H2 Blocking Agents Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Antispasmodic and Anticholinergic H2 Blocking Agents Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Antispasmodic and Anticholinergic H2 Blocking Agents Demand Share Forecast, 2019-2026
9. North America Antispasmodic and Anticholinergic H2 Blocking Agents Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Antispasmodic and Anticholinergic H2 Blocking Agents Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Antispasmodic and Anticholinergic H2 Blocking Agents Market Size and Volume Forecast by Application
9.4.1. Intestinal and Renal Colic Cramps
9.4.2. Diarrhoea
9.4.3. Spastic Constipation
9.4.4. Gastritis
9.4.5. Dysmenorrhea
9.4.6. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Antispasmodic and Anticholinergic H2 Blocking Agents Market Size and Volume Forecast by Type
9.7.1. Oral
9.7.2. Parenteral
9.7.3. Topical
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Antispasmodic and Anticholinergic H2 Blocking Agents Demand Share Forecast, 2019-2026
10. Latin America Antispasmodic and Anticholinergic H2 Blocking Agents Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Antispasmodic and Anticholinergic H2 Blocking Agents Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Antispasmodic and Anticholinergic H2 Blocking Agents Market Size and Volume Forecast by Application
10.4.1. Intestinal and Renal Colic Cramps
10.4.2. Diarrhoea
10.4.3. Spastic Constipation
10.4.4. Gastritis
10.4.5. Dysmenorrhea
10.4.6. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Antispasmodic and Anticholinergic H2 Blocking Agents Market Size and Volume Forecast by Type
10.7.1. Oral
10.7.2. Parenteral
10.7.3. Topical
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Antispasmodic and Anticholinergic H2 Blocking Agents Demand Share Forecast, 2019-2026
11. Europe Antispasmodic and Anticholinergic H2 Blocking Agents Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Antispasmodic and Anticholinergic H2 Blocking Agents Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Antispasmodic and Anticholinergic H2 Blocking Agents Market Size and Volume Forecast by Application
11.4.1. Intestinal and Renal Colic Cramps
11.4.2. Diarrhoea
11.4.3. Spastic Constipation
11.4.4. Gastritis
11.4.5. Dysmenorrhea
11.4.6. Others
11.5. Basis Point Share (BPS) Analysis by Application
116. Y-o-Y Growth Projections by Application
11.7. Europe Antispasmodic and Anticholinergic H2 Blocking Agents Market Size and Volume Forecast by Type
11.7.1. Oral
11.7.2. Parenteral
11.7.3. Topical
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Antispasmodic and Anticholinergic H2 Blocking Agents Demand Share, 2019-2026
12. Asia Pacific Antispasmodic and Anticholinergic H2 Blocking Agents Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Antispasmodic and Anticholinergic H2 Blocking Agents Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Antispasmodic and Anticholinergic H2 Blocking Agents Market Size and Volume Forecast by Application
12.4.1. Intestinal and Renal Colic Cramps
12.4.2. Diarrhoea
12.4.3. Spastic Constipation
12.4.4. Gastritis
12.4.5. Dysmenorrhea
12.4.6. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Antispasmodic and Anticholinergic H2 Blocking Agents Market Size and Volume Forecast by Type
12.7.1. Oral
12.7.2. Parenteral
12.7.3. Topical
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Antispasmodic and Anticholinergic H2 Blocking Agents Demand Share, 2019-2026
13. Middle East & Africa Antispasmodic and Anticholinergic H2 Blocking Agents Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Antispasmodic and Anticholinergic H2 Blocking Agents Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Antispasmodic and Anticholinergic H2 Blocking Agents Market Size and Volume Forecast by Application
13.4.1. Intestinal and Renal Colic Cramps
13.4.2. Diarrhoea
13.4.3. Spastic Constipation
13.4.4. Gastritis
13.4.5. Dysmenorrhea
13.4.6. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Antispasmodic and Anticholinergic H2 Blocking Agents Market Size and Volume Forecast by Type
13.7.1. Oral
13.7.2. Parenteral
13.7.3. Topical
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Antispasmodic and Anticholinergic H2 Blocking Agents Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Antispasmodic and Anticholinergic H2 Blocking Agents Market: Market Share Analysis
14.2. Antispasmodic and Anticholinergic H2 Blocking Agents Distributors and Customers
14.3. Antispasmodic and Anticholinergic H2 Blocking Agents Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Demeton
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Alaven Pharmaceutical
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. lriSys
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Meda Pharmaceuticals
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Fougera Pharmaceuticals
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Valeant Pharmaceuticals International
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. LUITPOLD PHARMS
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. FOREST LABS INC
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. MylanPharmaceuticals
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Pioneer Pharmaceuticals
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Watson Laboratories
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Lannett
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
&
